Gossamer Bio Inc (NASDAQ:GOSS)

8.91
Delayed Data
As of Nov 25
 -0.12 / -1.33%
Today’s Change
5.64
Today|||52-Week Range
15.20
-21.22%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$845.4M

Company Description

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Contact Information

Gossamer Bio, Inc.
3013 Science Park Road
San Diego California 92121
P:(858) 684-1300
Investor Relations:

Employees

Shareholders

Other institutional54.67%
Mutual fund holders26.14%
Individual stakeholders16.92%

Top Executives

Faheem HasnainChairman, President & Chief Executive Officer
Bryan GiraudoChief Operating & Financial Officer
Richard ArandaChief Medical Officer
Laura CarterChief Scientific Officer
Christian WaageSecretary, General Counsel & Executive VP